Role of PPARg2 transcription factor in thiazolidinedione-induced insulin sensitization

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 2, 2012, Pages 161-171

  Saraf, Neha ^a   Sharma, Promod K ^a   Mondal, Sambhu C ^a   Garg, Vipin K ^a   Singh, Avnesh K ^a  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

insulin resistance; insulin sensitivity; PPARg2; Pro12Ala variant; thiazolidinediones

Indexed keywords

ADIPONECTIN; CIGLITAZONE; GLITAZONE DERIVATIVE; INSULIN; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR FKHR; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOGENESIS; ANEMIA; ANTIDIABETIC ACTIVITY; CLINICAL FEATURE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIZATION; DRUG STRUCTURE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE STRUCTURE; GENE TARGETING; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DISEASE; LIVER INJURY; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2 GENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR BINDING; REGULATOR GENE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; UPREGULATION; WEIGHT GAIN;

ADIPOCYTES; ADIPOSE TISSUE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; PPAR GAMMA; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 84855447818     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01366.x     Document Type: Review

References (83)

1. Kershaw EE, Flier JS,. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556. (Pubitemid 38766330)
2. Mayas MD, et al,. Inverse relation between FASN expression in human adipose tissue and the insulin resistance level. Nutr Metab 2010; 7: 1186-1743.
3. Klaus S,. Adipose tissue as a regulator of energy balance. Curr Drug Targets 2004; 5: 241-250. (Pubitemid 38372310)
4. Yu JG, et al,. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese and type 2 diabetic subjects. Diabetes 2002; 51: 2968-2974.
5. Lehrke M, Lazar MA,. The many faces of PPARg. Cell 2005; 23: 993-999.
6. Mohamed Ali V, et al,. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 1998; 22: 1145-1158.
7. Maeda N, et al,. PPARg Ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001; 50: 2094-2099. (Pubitemid 33643677)
8. Guo L, Tabrizchi R,. Peroxisome proliferator-activated receptor gamma as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther 2006; 11: 145-173. (Pubitemid 43765533)
9. Gaidhu MP, et al,. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol 2009; 298: C961-C971.
10. Schoenborn V, et al,. brief genetics report, the ATGL gene is associated with free fatty acids, triglycerides, and Type 2 diabetes. Diabetes 2006; 55: 1270-1275. (Pubitemid 44195364)
11. 2 (AdPLA). J Biol Chem 2008; 283: 25428-25436.
12. Krook A, et al,. Molecular mechanisms regulating glucose uptake. Med Sci Sports Exerc 2004; 36: 1212-1217. (Pubitemid 38878998)
13. Rangwala SM, Lazar MA,. Peroxisome proliferator activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 2004; 25: 331-336. (Pubitemid 38692426)
14. Liu RH, et al,. Early events involved in the development of insulin resistance in Zucker fatty rat. Int J Obes Relat Metab Disord 2002; 26: 318-326. (Pubitemid 34226156)
15. rd edn. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, 2009: 440-446.
16. Gouda HN, et al,. The association between the peroxisome proliferator-activated receptor-g2 (PPARG2) Pro12Ala gene variant and Type 2 diabetes mellitus: a huge review and meta-analysis. Am J Epidemiol 2010; 171: 645-655.
17. Olesky JM,. Diabetes Mellitus: a Fundamental and Clinical Text. Philadelphia, PA: Lippincott Williams and Wilkins, 2004: 441-453.
18. Birubaum MJ,. Identification of a novel gene encoding an insulin-responsive glucose transporter protein. Cell 1989; 57: 305-315.
19. Heikkinen S, et al,. The Pro12Ala PPARg2 variant determines metabolism at the gene-environment interface. Cell met 2009; 9: 88-98.
20. Altshuler D, et al,. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000; 26: 76-80.
21. Deeb SS, et al,. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287. (Pubitemid 28507675)
22. Ek J, et al,. Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia 1999; 42: 892-895. (Pubitemid 29325082)
23. Mangelsdorf DJ, et al,. The nuclear receptor superfamily: the second decade. Cell 1995; 83: 835-839.
24. Issemann I, Green S,. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-650.
25. Nolte RT, et al,. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998; 395: 137-143. (Pubitemid 28425645)
26. Stumvoll M, Haring H,. The peroxisome proliferator-activated receptor gamma2 Pro12Ala polymorphism. Diabetes 2002; 51: 2341-2347. (Pubitemid 34827380)
27. Ristow M, et al,. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N Engl J Med 1998; 339: 953-959. (Pubitemid 28455097)
28. Barroso I, et al,. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
29. Chawla A, et al,. Nuclear receptors and lipid physiology: opening the X-files. Science 2001b; 294: 1866-1870.
30. Puig V, et al,. Peroxisome proliferator-activated receptor gene expression in human tissues, effects of obesity, weight loss and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99: 2416-2422.
31. Heuvel VJ,. The PPAR resource page. Biochim Biophys Acta 2007; 1771: 1108-1112.
32. Gouda HN, et al,. The association between the peroxisome proliferator-activated receptor-γ2 (PPARG2) Pro12Ala gene variant and Type 2 diabetes mellitus: a huge review and meta-analysis. Am J Epidemiol 2010; 171: 645-655.
33. Spiegelman BM,. PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514. (Pubitemid 28160438)
34. Mukherjee R, et al,. Identification characterization and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071-8076. (Pubitemid 27137374)
35. Auwerx J,. PPARgamma, the ultimate thrifty gene. Diabetologia 1999; 42: 1033-1049.
36. Fajas L, et al,. The organization, promoter analysis and expression of the human PPARgamma gene. J Biol Chem 1997; 272: 18779-18789. (Pubitemid 27318225)
37. Tontonoz P, et al,. mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev 1994a; 8: 1224-1234.
38. Laplante M, et al,. Mechanism of the depot specificity of peroxisome proliferator-activated receptor gamma action on adipose tissue metabolism. Diabetes 2003; 55: 2771-2778. (Pubitemid 44923676)
39. Festuccia WT, et al,. Depot specific effect of the PPARgamma agonist vosiglitazone on adipose tissue glucose uptake and metabolism. J Lipid Res 2009; 50: 1185-1194.
40. Desvergne B, Wahli W,. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999b; 20: 649-688. (Pubitemid 30650602)
41. Nagy L, et al,. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93: 229-240. (Pubitemid 28180856)
42. McIntyre TM, et al,. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc Natl Acad Sci USA 2003; 100: 131-136. (Pubitemid 36078041)
43. Schopfer FJ, et al,. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci USA 2005; 102: 2340-2345. (Pubitemid 40279377)
44. Chen JD, Evans RM,. A transcriptional co-repressor that interacts with nuclear hormone receptor. Nature 1995; 377: 454-457.
45. Xu L, et al,. Co-activator and corepressor compexes in nuclear receptor function. Curr Opin Genet Dev 1999; 9: 140-147.
46. Hu X, Lazar MA,. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptor. Nature 1999; 402: 93-96.
47. Paracchini V, et al,. Genetics of leptin and obesity: a HuGE review. Am J Epidemiol 2005; 162: 101-114. (Pubitemid 41373535)
48. Soriguer F, et al,. Pro12Ala polymorphism of the PPARG2 gene is associated with Type 2 Diabetes mellitus and peripheral insulin sensitivity in a population with a high intake of oleic acid. J Nutr 2006; 136: 2325-2330. (Pubitemid 44329990)
49. MacDougald OA, Mandrup S,. Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 2002; 13: 5-11. (Pubitemid 36734009)
50. Chawla A, et al,. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology 1994; 135: 798-800. (Pubitemid 24241266)
51. Marx N, et al,. PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol 1999; 19: 546-551. (Pubitemid 29135154)
52. Ricote M, et al,. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82. (Pubitemid 28079218)
53. Sarraf P, et al,. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998; 4: 1046-1052. (Pubitemid 28417337)
54. Meirhaeghe A, Amouyel P,. Impact of genetic variation of PPARγ in humans. Mol Genet Met 2004; 83: 93-102. (Pubitemid 39311284)
55. Uno K, et al,. Neuronal pathway from the liver modulates energy expenditure and systemic insulin sensitivity. Science 2006; 312: 1656-1659. (Pubitemid 43902665)
56. Rangwala SM, et al,. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev Cell 2003; 5: 657-663. (Pubitemid 37243053)
57. Adams M, et al,. Transcriptional activation by PPARγ is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 1997; 272: 5128-5132. (Pubitemid 27090069)
58. Camp HS, Tafuri SR,. Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase. J Biol Chem 1997; 272: 13452-13457.
59. Berger J, et al,. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology 1996; 137: 4189-4195. (Pubitemid 26321865)
60. Willson TM, et al,. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 1996; 39: 665-668.
61. Activtox human liver cell systems. Structure toxicity relationships-thiazolidinediones. Available online at: http://www.activtox.com/ hepatotoxicity/str.php?family=thiazolidinediones.
62. Fujita T, et al,. Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]- thiazolidine-2, 4-dione (ADD-3878, U-63287, ciglitazone), a new antidiabetic agent. Diabetes 1983; 32: 804-810. (Pubitemid 13038896)
63. Patel J, et al,. Rosiglitazone monotherapy improves glycaemic control in patients with type-2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabet Obes Metab 1999; 1: 165-172.
64. Bhattarai BR, et al,. Novel thiazolidinedione derivatives with anti-obesity effects: dual action as PTP1B inhibitors and PPAR-γ activators. Bioorg Med Chem Lett 2010; 20: 6758-6763.
65. Souza SC, et al,. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones. Diabetes 1998; 47: 4691-4695.
66. Brunmair B, et al,. Direct thiazolidinedione action on isolated rat skeletal muscle fuel handling is independent of peroxisome proliferator- activated receptor-γ-mediated changes in gene expression. Diabetes 2001; 50: 2309-2315. (Pubitemid 33641916)
67. Greenfielz JR, Chisholm DJ,. Thiazolidinediones-mechanisms of action. Exp clin Pharmacol 2004; 27: 67-70.
68. Malecki MT,. Genetics of type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 68: S10-S21. (Pubitemid 40805487)
69. Saltiel AR, Olefsky JM,. Thiazolidinediones in the treatment of insulin resistance and type 2 diabetes. Diabetes 1996; 45: 1661-1669. (Pubitemid 26398943)
70. Berger J, et al,. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem 1999; 274: 6718-6725. (Pubitemid 29111093)
71. Bark Y, et al,. PPARgamma is required for the placental, cardiac and adipose tissue development. Met Cell 1999; 4: 611-617.
72. Rosen ED, et al,. PPARgamma is required for the differentiation of adipose tissue in vivo and in vitro. Mel Cell 1999; 4: 600-617.
73. Kumar ACK, et al,. Oral hyperglycaemic agents for treatment of type-2 diabetes mellitus: a review. Pharmaceutical Reviews 2008; 6:(1).
74. Aldhahi W, Hamdy O,. Adipokines, inflammation and the endothelium in diabetes. Curr Diab Rep 2003; 3: 293-298.
75. Spiegelman BM,. Perspectives in diabetes PPAR-γ: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 509-512.
76. Zhang L, et al,. Gsa signalling suppresses PPARg2 generation and inhibits 3T3L1 Adipogenesis. J Endocrinol 2009; 202: 207-215.
77. Simpson RG, et al,. Early phase of insulin release. Diabetes 1968; 17: 684-692.
78. Cerasi E, et al,. Decreased sensitivity of the pancreatic β cell to glucose in prediabetic and diabetic subjects, a glucose dose response study. Diabetes 1972; 21: 224-234.
79. Pihlajamaki J, et al,. The Pro12Ala substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia. Atherosclerosis 2000; 151: 567-574. (Pubitemid 30618776)
80. Evangelisti L, et al,. PPARgamma promoter polymorphisms and acute Coronary syndrome. Atherosclerosis 2009; 205: 186-191.
81. Luo W, et al,. Adipose tissue-specific PPARγ deficiency increases resistance to oxidative stress. Exp Gerontol 2008; 43: 154-163.
82. Heikkinen S, et al,. PPARγ in human and mouse physiology. Biochim Biophys Acta 2007; 1771: 999-1013.
83. Lee BC, et al,. Peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neuro Letts 2006; 410: 141-145. (Pubitemid 44709410)